Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.
CureVac N.V. (NASDAQ: CVAC) is a multinational biopharmaceutical and biotech company focused on medicines based on messenger RNA (mRNA). Founded in 2000 and headquartered in Tübingen, Germany, CureVac describes itself as a pioneer in mRNA technology, with more than two decades of experience in developing, optimizing, and manufacturing mRNA for medical use. Its public communications highlight work in oncology precision immunotherapies, prophylactic vaccines, and mRNA-based treatments that aim to enable the body to produce therapeutic proteins.
The CVAC news feed features company announcements on clinical development milestones, regulatory decisions, intellectual property rulings, and financial results. Examples include updates on Phase 1 studies for off-the-shelf precision immunotherapies in glioblastoma and squamous non-small cell lung cancer, progress in a urinary tract infection vaccine program, and regulatory clearances such as U.S. FDA Investigational New Drug approvals and European Medicines Agency Clinical Trial Application decisions.
Investors and observers will also find news on patent litigation and IP protection, particularly proceedings at the European Patent Office and German courts involving patents that describe split poly-A tail technology, as well as agreements with BioNTech and Pfizer regarding mRNA-based COVID-19 vaccines. In addition, CureVac regularly reports quarterly and annual financial results, cash position, and the effects of restructuring and licensing agreements with partners like GSK and CRISPR Therapeutics.
Recent releases describe a definitive purchase agreement under which BioNTech intends to acquire all shares of CureVac via a public exchange offer, along with shareholder voting results and steps toward a post-offer reorganization. For anyone tracking CVAC, this news page provides a centralized view of CureVac’s scientific, clinical, legal, financial, and corporate developments over time.
CureVac N.V. (NASDAQ:CVAC) announced the results of its annual general meeting where shareholders approved most proposals, notably the appointments of Antony Blanc and Klaus Edvardsen as managing directors, and the re-appointment of Pierre Kemula. However, they rejected the authorization for the management board to acquire shares. The company emphasizes its focus on mRNA technology, leveraging over 20 years of expertise to develop innovative therapies across various domains.
CureVac N.V. (NASDAQ:CVAC) announced significant changes to its Supervisory Board. Dr. Ingmar Hoerr has withdrawn his candidacy due to ongoing health issues, while Dr. Timothy M. Wright has resigned to focus on personal endeavors. Both were recognized for their contributions to the company, with Hoerr credited for advancing mRNA technology. CureVac continues to develop transformative mRNA-based medicines and has a diverse clinical pipeline targeting vaccines, cancer therapies, and rare diseases. The company remains committed to its innovative approach in the biopharmaceutical sector.
CureVac (NASDAQ:CVAC) announced its second interim analysis of the HERALD study, which evaluated its COVID-19 vaccine candidate CVnCoV. Conducted across 10 countries with approximately 40,000 participants, the analysis revealed an interim efficacy of 47% against COVID-19; however, it did not meet the statistical success criteria. The safety profile remained favorable. Out of 134 assessed cases, 57% were due to variants of concern. The study is progressing towards a final analysis, with results shared with the European Medicines Agency (EMA). CureVac is also advancing second-generation vaccine candidates.
CureVac N.V. (NASDAQ:CVAC) announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer, effective August 1, 2021. His extensive experience in clinical and product development, particularly in oncology, is expected to guide CureVac's transition into a fully integrated biopharmaceutical company. Edvardsen previously held senior roles at Merck KGaA and AstraZeneca, enhancing his capability to advance CureVac's mRNA technology and clinical pipeline. The company remains focused on mRNA therapeutics, including its COVID-19 vaccine candidate, CVnCoV.
CureVac announced promising preclinical results for its second-generation COVID-19 vaccine candidate, CV2CoV, developed in collaboration with GSK. The vaccine demonstrates high levels of antigen production and strong, fast-acting immune responses in rat models. Notably, CV2CoV elicited significant cross-neutralizing antibodies against variants of concern such as those from Denmark, the UK, and South Africa. The candidate is engineered for improved stability and efficacy, with clinical trials expected to commence in Q3 2021, aiming for broad protection against emerging strains.
CureVac N.V. (NASDAQ: CVAC) reported significant progress in its COVID-19 vaccine candidate CVnCoV, now in the final stage of clinical development with over 40,000 participants in a pivotal study across Europe and Latin America. The company anticipates interim efficacy data in Q2 2021. With a strong cash position of €1.32 billion as of December 31, 2020, and an additional $517.5 million raised in early 2021, CureVac is well-positioned for growth. Partnerships with Bayer, GSK, and the UK government aim to expedite vaccine development and expand production capacity to 1 billion doses by 2022.
CureVac N.V. (Nasdaq:CVAC) will announce its financial results and business updates for Q4 and the full year 2020 on April 15, 2021. A conference call and webcast will be held at 4:00 p.m. CET / 10:00 a.m. EST. Investors can access the webcast on the CureVac Investor Relations page. CureVac is focused on transformative medicines utilizing mRNA technology to create vaccines and therapies across various diseases. The company emphasizes its extensive experience in developing mRNA for medical applications.
CureVac N.V. (Nasdaq: CVAC) announced promising preclinical data for its COVID-19 vaccine candidate, CVnCoV, demonstrating protection against the SARS-CoV-2 variant B.1.351 (South African variant) in transgenic mice. The study showed that CVnCoV induced robust antibody responses, achieving full protection (100% survival) against both the original virus and the variant strain following a two-dose vaccination schedule. The vaccine effectively blocked viral replication in infected mice, underscoring its potential in combating emerging SARS-CoV-2 variants.
CureVac (Nasdaq:CVAC) is enhancing its late-stage clinical trials for its COVID-19 vaccine candidate, CVnCoV, in response to new variants. The pivotal HERALD Phase 2b/3 trial will now include select strains for a case-driven analysis. Additionally, a protocol amendment for the Phase 2a trial in older adults will add a secondary efficacy endpoint. CureVac aims for market authorization by Q2 2021 and anticipates data readouts from both trials in the same quarter.
CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac's COVID-19 vaccine candidate, CVnCoV. Production is set to begin in Q2 2021, aiming for up to 50 million doses by the end of 2021, and an additional 200 million doses in 2022 at Novartis' Kundl site in Austria. This collaboration enhances CureVac's European manufacturing network, expected to boost capacity significantly. The agreement is part of CureVac's ongoing development of mRNA-based vaccines initiated in January 2020, with prior successful clinical trials.
FAQ
What is the current stock price of Curevac B.V. (CVAC)?
What is the market cap of Curevac B.V. (CVAC)?
